Policy & Regulation
INOVIO and IVI partner with Seoul National University Hospital to launch trial of COVID-19 vaccine
4 June 2020 -

INOVIO (NASDAQ:INO), the International Vaccine Institute (IVI) and Seoul National University Hospital announced on Wednesday announced a partnership to start a Phase 1/2 clinical trial of INOVIO's COVID-19 vaccine INO-4800 in South Korea.

The two-stage trial of INO-4800 will assess the safety, tolerability and immunogenicity of the candidate vaccine in 40 healthy adults aged 19-50 years and will expand to enrol an additional 120 people aged 19-64 years.

The trial is reportedly funded by the Coalition for Epidemic Preparedness Innovations (CEPI) through INOVIO and is supported by the Korea Center for Disease Control and Prevention/Korea National Institute of Health.

Speedy regulatory approval for the trial was made possible with support from the Korean Ministry of Food and Drug Safety following its adoption in April of a fast-track approval process for clinical trials of COVID-19 vaccines and therapeutics that are developed with a proven safety platform.



Related Headlines